One Kendall Square
Building 1400W, 2nd Floor
130 articles with Quanterix
NuProbe Global announced today the formation of its Scientific Advisory Board (SAB) with genomics pioneers George M. Church, Ph.D. and David R. Walt, Ph.D.
Quanterix’ Ultra-Sensitive Technology Creates Breakthroughs in Brain Health of Military and Veterans
New research advances the diagnosis of concussions and PTSD for those in the line of duty
EY Announces Kevin Hrusovsky, President, Chairman and Chief Executive Officer of Quanterix and Founder of Powering Precision Health as an Entrepreneur Of The Year® 2018 Award Finalist in the New England Region
Quanterix Corporation announced that Kevin Hrusovsky, President, Chairman and CEO of Quanterix, and Founder of Powering Precision Health (PPH), has been named by EY as a finalist for the Entrepreneur Of The Year® 2018 Award in the New England program.
Quanterix to Release First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it will release its financial results for first quarter 2018 after the close of trading on Wednesday, May 9, 2018
Researchers are increasingly choosing Quanterix’ ultra-sensitive technology to power advancements in neurology
Quanterix Corporation and DestiNA Genomics to Collaborate in Effort to Transform microRNA Biomarker Detection
Collaboration offers potential for PCR-free microRNA biomarker detection with high-specificity and ultra-sensitivity
Arbor Biotechnologies came out of stealth mode yesterday with a $15.6 million Series A financing round.
Quanterix Corporation reported financial results for the fourth quarter and full year of 2017. Revenues for full year 2017 of $22.9M were at the high end of the range of $22.5-$22.9M, which was previously announced in January 2018.
New Research Demonstrates Enhanced Sensitivity for Acute HIV Detection Using Quanterix’ Simoa Technology
Quanterix Corporation announced its industry-leading single molecule array, or Simoa, technology has achieved enhanced sensitivity for the detection of acute HIV infection relative to currently approved fourth-generation antigen-antibody (Ag/Ab) combination (combo) and stand-alone p24 assays.
The company believes its ultrasensitive immunoassay technology is well-suited to pharma research.
The Company’s latest instrument, powered by Simoa technology, opens the door for researchers to access ultra-sensitive protein and nucleic acid detection capabilities in a more compact and affordable system.
12/12/2017A look at what three ex-Genentech employees have accomplished at Denali so far.
Quanterix announced the closing of its initial public offering of 4,916,480 shares of common stock at a public offering price of $15.00 per share, including 641,280 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares.
Quanterix Corporation announced the pricing of its initial public offering of 4,275,200 shares of its common stock at a public offering price of $15.00 per share for aggregate gross proceeds of $64,128,000.
The current expected initial public offering price is between $14.00 and $16.00 per share.
Quanterix To Launch High-Sensitivity Benchtop Instrument And Assays For Multiplex Biomarker Detection
Quanterix Raises $8.5 Million In Private Financing Led By T. Rowe Price Associates; Also Appoints Dr. Marijn Dekkers To Company’s Board Of Directors And Several Key Executives To Its Leadership Team